AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04557566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EBT yoga-based eating disorder course
Description: Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
Study NCT06236204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Scapholunate Ligament Reconstruction
Description: reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
Study NCT05546931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching application
Description: A digital application for providing education and support for home-based blood pressure monitoring.
Study NCT05546931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WebMD
Description: Smartphone-based application for health education and/or monitoring.
Study NCT05546931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based blood pressure monitoring
Description: Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
Study NCT05546931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based blood pressure monitoring
Description: Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
Study NCT05037513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBCM-PrEP
Description: Multi-session SBCM intervention adapted for PrEP initiation focus
Study NCT05037513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC-PrEP
Description: 1 session PrEP education following CDC guidelines
Study NCT05245877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin/tinzaparin/dalteparin
Description: Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
Study NCT04842305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood- and saliva tests
Description: Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
Study NCT06334874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin Oral Capsule
Description: 12 mg of astaxanthin oral capsule
Study NCT06334874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch placebo capsule
Study NCT05941260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computational fluid dynamics (CFD)
Description: - Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery.
Study NCT04937296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
Study NCT04937296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care.
Study NCT06018714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules.
Study NCT05407415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kardia Mobile 6L Device
Description: The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician).
Study NCT04190524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Application of cricoid pressure
Description: The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
Study NCT04190524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Application of Left lateral paratracheal pressure
Description: Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
Study NCT05547789 — intervention group
Intervention type: DRUG
Intervention: non steroidal anti inflammatory drugs
Description: effect of non steroidal anti inflammatory drugs on macular changes
Study NCT04891185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
Study NCT05977166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
Study NCT05977166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: breathing exercise
Description: All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
Study NCT05977166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
Study NCT05322330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 40-60mg QW,w-3～d-3,PO
Study NCT05322330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu
Description: 25-30 mg/m2，d-5 ～d-3，qd，ivgtt
Study NCT05322330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: 250-500 mg/m2，d-5 ～d-3，qd，ivgtt
Study NCT05322330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: 2-5×10\^6 CAR-T/kg，ivgtt。
Study NCT05340179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interlaminar cervical epidural injection
Description: Fluoroscopy-guided interlaminar cervical epidural injection
Study NCT05340179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical selective nerve root block
Description: Ultrasound-guided cervical selective nerve root block
Study NCT06152497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT06152497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 blockade: Telfast: 180mg Fexofenadine
Description: H1 blockade: oral blockade with 180mg Fexofenadine
Study NCT06152497 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Resistance training: lower body exercise
Study NCT06152497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training: lower body exercise
Study NCT04468191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental expiratory muscle strength training (EMST)
Description: The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
Study NCT04468191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham expiratory muscle strength training (EMST)
Description: The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
Study NCT05687214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum.
Study NCT04772144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural and cessation aids
Description: information, motivational interview, refferal to healty life-centers, free cessation aids
Study NCT05833451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
Study NCT06500546 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of cervical lesions
Description: Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,
Study NCT05880329 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Candidate POCTs for detecting UTI
Description: POCT performance will be evaluated in participants who experience possible UTI.
Study NCT06477432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mesofiller® mesotox
Description: The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
Study NCT06477523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion
Study NCT06477523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT06477523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT06477523 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy
Description: The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy).
Study NCT04841928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful attention
Description: The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Study NCT04841928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentering
Description: The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Study NCT04841928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value-based action
Description: The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Study NCT05224856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P63 and CT-P66 / Placebo
Description: Inhalation
Study NCT05224856 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CT-P63 and CT-P66 / Placebo
Description: Inhalation
Study NCT04938453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib 25 mg
Description: soft gelatin capsule
Study NCT04938453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib 100 mg
Description: soft gelatin capsule
Study NCT05866432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Will be given until PD or withdraw
Study NCT06169566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotics
Description: synbiotics
Study NCT06169566 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04473989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant teriparatide for injection
Description: weekly subcutaneous administration of 40 ug
Study NCT04473989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly subcutaneous administration of 40 ug
Study NCT05647889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jet lidocaine
Description: Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
Study NCT05647889 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ice
Description: Ice will be applied for 1 minute before PVC, and then PVC will be performed.
Study NCT05647889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVC procedure
Description: Standard PVC procedure will be applied
Study NCT06524830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-01-203 BU
Description: Buccal administration of VLS-01
Study NCT06524830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VLS-01-BU Placebo
Description: Buccal administration of VLS-01 Placebo
Study NCT05587166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided adductor canal block
Description: ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
Study NCT05887609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
Study NCT05887609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
Study NCT05159271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Azeol spray nasal
Description: Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
Study NCT05159271 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
Study NCT05042531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
Study NCT05042531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
Study NCT05042531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: dasatinib,20mg,po,qd,treatment cycles every 28 days
Study NCT05458466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
Study NCT05147155 — intervention group
Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.